Insulin resistance and chronic kidney disease progression, cardiovascular events, and death: findings from the chronic renal insufficiency cohort study

Chronic kidney disease (CKD) affects up to 26 million Americans, resulting in a disproportionate risk of cardiovascular disease and end-stage renal disease (ESRD) [1]. The strong association of CKD with cardiovascular disease is explained only in part by traditional risk factors, and it is hypothesized that metabolic or inflammatory abnormalities associated with progressive renal disease, such as insulin resistance, confer an augmented risk of cardiovascular disease in CKD [2‐5]. Insulin resistance is a pathological state in which tissues have a decreased sensitivity to insulin, leading to a compensatory rise in circulating insulin to maintain normal blood glucose levels [6‐9]. Increased levels of insulin have been reported to be an important risk factor for the development of atherosclerosis in the general population [10, 11].

Insulin resistance is present in the early stages of CKD [12‐15], and becomes more prevalent as CKD progresses [16]. However, the precise mechanisms of insulin resistance in CKD remains poorly identified [8]. Further, due to the exclusion of individuals with CKD in many epidemiologic studies of insulin resistance, it is unclear if insulin resistance alone contributes to an increased risk of important clinical outcomes in CKD [17].

In this study, we examined factors associated with insulin resistance in CKD and investigated the association of insulin resistance, and markers of carbohydrate metabolism, with subsequent CKD progression, atherosclerotic cardiovascular events, and all-cause mortality among individuals with mild-moderate CKD without diabetes.

A total of 1883 CRIC Study participants did not have diabetes at study entry. These participants had a mean age of 56.5 years, a mean BMI of 30.3 kg/m², and a mean eGFR of 49 mL/min/1.73m². Mean values for HOMA-IR, glucose, insulin, HbA1c, and C-peptide were 3.84, 5 mmol/L, 0.6 μg/L, 39 mmol/mol, and 3.0 μg/L, respectively. Baseline characteristics are reported by quartile of HOMA-IR in Table 1. (Due to the positively skewed nature of the distribution of HOMA-IR values, which causes Quartile 4 to contain a much wider range of values than Quartiles 1–3, that quartile is divided in two.) History of cardiovascular disease, BMI, waist circumference, statin use, hsCRP, glucose, insulin, HbA1c, and C-peptide all increased with the upper quartiles of HOMA-IR. Notably, components of the metabolic syndrome (central obesity as measured by waist circumference, fasting glucose, triglycerides, and HDL) trended as expected with increasing quartiles of HOMA-IR. HOMA-IR was strongly correlated with C-peptide (r = 0.78), moderately correlated with glucose (r = 0.54), and weakly correlated with HbA1c (r = 0.26).

Several baseline characteristics were significantly associated with log₂-HOMA-IR (Tables 2 and 3): age per year (β = 0.005, p = 0.001), non-smoking vs. current smoking (β = 0.13, p = 0.002), BMI per kg/m² (β = 0.02, p < 0.001), waist circumference per centimeter (β = 0.01, p < 0.001), hemoglobin per mmol/L (β = 0.04, p < 0.001), LDL per mmol/L (β = − 0.002 p < 0.001), HDL per mmol/L (β = − 0.003, p = 0.001), triglycerides per mmol/L (β = 0.30, p < 0.001), and hsCRP per nmol/L (β = 0.04, p = 0.03). In the exploratory linear regression, the following were found to be associated with HOMA-IR: use of non-statin lipid lowering medications vs. non-use (β = − 0.16, p = 0.03), serum albumin per g/L (β = 0.12, p = 0.001), HbA1c per mmol/mol (β = 0.2, p < 0.001), and uric acid per umol/L (β =0.03, p = 0.001).

The median (IQR) duration of follow-up was 7.76 (3.40–10.26) years for the composite renal endpoint, with 474 renal events (event rate 3.68 per 100 person-years), 9.43 (5.95–10.81) years for the composite cardiovascular endpoint with 220 cardiovascular events (event rate: 1.43 per 100 person-years), and 10.15 (9.74–11.09) years for mortality with 379 deceased during follow-up (event rate: 2.19 per 100 person-years; Table 4). The assumption of proportionality was met in the fully adjusted Cox models.

HOMA-IR was not significantly associated with CKD progression, atherosclerotic cardiovascular events, or all-cause mortality (Table 5). For each 1 SD higher in HbA1c there was a 16% greater rate of the cardiovascular endpoint (HR 1.16, 95% CI: 1.00–1.34). The finding was consistent in adjusted models censored at ESRD (HR 1.25, 95% CI 1.06–1.47; Additional file 1 Table S1) and when modeling death as a competing event (HR 1.18, 95% CI: 1.01–1.39; Additional file 1 Table S2). For each 1 SD higher fasting glucose, there was a 12% lower rate of CKD progression (HR 0.88, 95% CI: 0.79–0.98).

In the present study, we examined factors that potentially contribute to insulin resistance, as measured by HOMA-IR, in individuals with mild-to-moderate CKD in the absence of diabetes, and investigated the association of HOMA-IR and other carbohydrate metabolism measures with CKD progression, atherosclerotic cardiovascular events, and all-cause mortality. We observed that age, current smoking, greater BMI and waist circumference, and higher hemoglobin, triglycerides and hsCRP were independently associated with HOMA-IR, which is consistent with prior reports. HOMA-IR was not significantly associated with CKD progression, atherosclerotic cardiovascular events, or all-cause mortality in adjusted models.

The current study is among the first to report significant associations of uric acid, serum albumin, HbA1c, and the use of non-statin lipid-lowering medications with HOMA-IR among non-diabetics with CKD. These associations were independent of age, sex, race, education and other risk factors, such as SBP, BMI, physical activity and eGFR. The use of non-statin lipid-lowering medications was negatively associated with HOMA-IR, a finding consistent with the prior observation that higher cholesterol levels have been associated with HOMA-IR [23, 24]. Hyperuricemia has been demonstrated to be strongly associated with abnormal glucose metabolism and insulin resistance, but to our knowledge this association has not been reported in nondiabetics with CKD [25, 26]. The positive association of HbA1c and HOMA-IR suggests chronic mild hyperglycemia and decreased sensitivity to insulin is present even in the absence of overt diabetes in those with mild-moderate CKD. Higher serum albumin levels and insulin resistance have also been associated in nondiabetic populations without kidney disease [27, 28]. Higher serum albumin in the setting of insulin resistance is thought to be the consequence of increased albumin production caused by insulin stimulation [29].

Many of the factors found to be independently associated with HOMA-IR in CKD are consistent with previous reports, in particular with body composition measures, which include BMI and fat mass in CKD patients without diabetes [30‐32, 12, 24, 30, 33]. It is postulated that the higher levels of inflammatory mediators found in visceral fat contributes to the development of insulin resistance [34, 35], which is consistent with our finding that waist circumference, BMI, and hsCRP were greater within higher quartiles of HOMA-IR. Systemic inflammation is thought to contribute to decreased tissue sensitivity to insulin and the increased risk of cardiovascular disease in CKD by driving endothelial dysfunction and atherosclerosis [36].

Despite the proposed link between insulin resistance, endothelial dysfunction, and atherosclerosis, the association of insulin resistance and cardiovascular events has not been consistent in the setting of kidney disease [12, 30, 37‐39]. A study by Shinohara et al. demonstrated that HOMA-IR was an independent predictor of cardiovascular mortality in nondiabetics with ESRD [37], but insulin resistance among those with earlier CKD, assessed with the gold standard for insulin resistance, the hyperinsulinemic euglycemic glucose clamp (HEGC) technique [30], or HOMA-IR [40], was not associated with new cardiovascular events. In the present study, we did not find HOMA-IR to be associated with the composite cardiovascular disease outcome. Interestingly, we found a trend for higher levels of HbA1c to be associated with an increased hazard of the cardiovascular endpoint, which suggests that mild elevations in blood glucose over time, even in the absence of overt diabetes, increase the risk of cardiovascular events in the setting of mild-moderate CKD. This finding is striking given that the positive association was observed in a range where we would not expect higher risk, and a recent report from the CRIC study found that HbA1c levels were not associated with incident type 2 diabetes [41]. A potential explanation could be that we included individuals with pre-diabetes into our study sample since enrollment blood glucose levels were below the level of exclusion. In a recent meta-analysis, pre-diabetes in the general population was associated with an increased risk of cardiovascular disease [42]. Mild hyperglycemia has also been reported to contribute to atherosclerosis in apparently healthy subjects and was independently associated with greater arterial stiffness in the CRIC Study [43, 44].

Hyperinsulinemia has been reported to influence kidney function by inducing glomerular hyperfiltration, endothelial dysfunction, and increased vascular permeability [45, 46]. However, there have been contradictory reports on the association of insulin resistance and CKD progression in those without diabetes. In several studies of populations with CKD, insulin resistance was associated with a more rapid decline in kidney function compared to those who were insulin sensitive [47, 40, 48]. However, in a prospective study of 73 non-diabetic participants with CKD, there was not a significant difference in eGFR between those who did and did not have insulin resistance (as measured by HOMA-IR) [49]. In the current study, we did not find an association of HOMA-IR, HbA1c, or C-peptide with CKD progression. Interestingly, higher levels of glucose were associated with decreased CKD progression, which is unexpected since HbA1c, the marker of prolonged hyperglycemia, was not associated with CKD progression. This finding should be further explored with longitudinal measures to better define the relationship.

Prior studies have not clearly demonstrated that insulin resistance predicts all-cause mortality in CKD [30, 37, 39]. In a cohort of 170 ESRD patients in Japan without diabetes, HOMA-IR predicted mortality independently of other risk factors, including inflammation and BMI [37], but in a cohort of nearly all non-diabetic elderly Caucasian men with mild-to-moderate CKD, insulin resistance was not associated with all-cause death, independent of classical risk factors. In the current study, HOMA-IR and the other markers of carbohydrate metabolism were not significantly associated with all-cause mortality.

The overall lack of association between HOMA-IR and important clinical endpoints in this study could be due to an imperfect estimate of insulin resistance in CKD. We utilized measures that largely reflect hepatic insulin resistance (i.e., fasting insulin and glucose) to calculate HOMA-IR, which does not capture peripheral insulin resistance (i.e. skeletal muscle) which is thought to be the primary location for insulin resistance in CKD [50]. A validation study of insulin sensitivity surrogates using a study sample of 1074 men, 495 with CKD (median eGFR 46 ml/min per 1.73m²) and without CKD deemed HOMA-IR a satisfactory surrogate as compared to HEGC technique [38]. However, the findings of the validation study might not extend to our study population since it was conducted in eldery men (age 70–71 years) from one region of Sweden with less obesity (all with BMI < 30 kg/m²).

The observational nature of the CRIC Study and the cross sectional analysis in identifying potential determinants of HOMA-IR are limitations of the current study, and do not allow us to establish causality. Since HOMA-IR was assessed only at baseline, we are not able to investigate for changes in HOMA-IR over the follow up period and subsequently, the impact of a change in HOMA-IR would have on the clinical outcomes of interest. Further, misclassification of diabetes status is also possible as it did not incorporate a measure of HbA1c.

Strengths of this study include the wealth of data collected through validated measures, which allowed for the assessment of associations of insulin resistance and other markers of carbohydrate metabolism that have been minimally explored, as well as the description of novel factors associated with insulin resistance in a population with mild-to-moderate CKD without diabetes. Additional strengths include the evaluation of the health implications of HOMA-IR over a broad range of eGFR values and across multiple racial/ethnic groups, which expands the generalization from other studies that were carried out on highly selected populations (e.g., only male or only Caucasian) with limited range of eGFR.

The results of the current study of participants with mild-moderate CKD in the absence of diabetes have demonstrated novel factors positively associated with HOMA-IR, including serum albumin, HbA1c, and uric acid. We also found consistent associations of body composition measures and systemic inflammation with HOMA-IR. HOMA-IR, fasting glucose, and C-peptide were not significantly associated with development of renal or atherosclerotic cardiovascular events, or all-cause mortality, which adds to the growing literature describing an inconsistent relationship of insulin resistance with important CKD-related outcomes. Assessment of peripheral rather than hepatic insulin resistance may better define the role of insulin resistance in mild-moderate CKD. Increased HbA1c was associated with an elevated hazard of the cardiovascular endpoint, suggesting that mild hyperglycemia, even in the absence of overt diabetes, may increase the risk of cardiovascular events in CKD. This finding should be further explored with longitudinal measures to better define the relationship.